Today

Agents

Chat

Arena

Discover

More

App

Cytokinetics to file FDA sNDA for aficamten in non-obstructive HCM in Q4 2026 - CYTK News | Rallies

Cytokinetics to file FDA sNDA for aficamten in non-obstructive HCM in Q4 2026

CYTK•2026-08-28

Phase 3 results support the move

The move follows positive Phase 3 ACACIA-HCM results, meeting dual primary endpoints at 36 weeks on KCCQ-CSS and pVO2.

Planned FDA filing for aficamten

Cytokinetics plans to file a supplemental New Drug Application with the FDA in Q4 2026 for aficamten in symptomatic non-obstructive HCM.

Related News

Dollar Tree Inc <DLTR.O>: Bernstein raises target price to $130 from $127

DLTR•2026-08-28

Dollar General Corp <DG.N>: Truist Securities raises target price to $138 from $114

DG•2026-08-28

17 Education CEO Liu Chang reports buying USD 24,659 of common shares

•

2026-08-28

Workday, Inc. <WDAY.O>: Wells Fargo raises target price to $225 from $215

WDAY•2026-08-28

Workday Inc <WDAY.O>: Morgan Stanley Raises Target Price to $180.00 From $145.00

WDAY•2026-08-28